Tag Archives: Qiagen

System Biosciences announced today that QIAGEN, a leading global provider of Sample to Insights solutions for molecular diagnostics and life sciences, has signed a non-exclusive, worldwide license for SBI's patented ExoQuick® technology for research use...

Pancreatic cancer is one of the most lethal malignancies with a poor prognosis. Liquid biopsies are non-invasive methods for diagnostics to detect early stage cancer resulting in more successful treatment. One liquid biopsy technique is the detection of RNA from ...

RNA-seq Explorer Solution generates clear insights for cancer ‘omics’ analyses Hilden, Germany, and Germantown, Maryland, April 14, 2016 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced introduction of its unique RNA-seq Explorer Solution, a bioinformatics-driven approach to ...

Liquid biopsies are non-invasive methods for diagnostics to detect early stage cancer resulting in more successful treatment. One liquid biopsy technique is the detection of RNA from tumor derived exosomes. Join our webinar to learn how bioinformatics solutions can be ...

Exosomes and other extracellular vesicles (commonly referred to as EVs) have generated a lot of attention for their potential applications in both diagnostics and therapeutics. The contents of these vesicles are the subject of intense research, and the relatively recent ...

A 4-part webinar series Part 3: Liquid biopsy: overcome challenges of cfDNA with automated and standardized extraction processes July 21, 9:30am EDT In this webinar, we present data on solutions for the following critical problems concerning the purification of cfDNA ...

The scientific literature contains a wide variety of isolation and characterization procedures for exosomes and other extracellular vesicles. Together with the variable nomenclature, this creates considerable difficulty when comparing results from different independent studies. An additional layer of variability is ...

GERMANTOWN, Maryland, and HILDEN, Germany, March 16, 2015 /PRNewswire/ — Acquisition of technology from AdnaGen enables use of innovative, non-invasive blood tests to analyze circulating tumor cells (CTCs) for personalized healthcare QIAGEN and Tokai Pharmaceuticals to co-develop and commercialize the ...

11:00 a.m. EST; 4:00 p.m. GMT Wednesday, October 15, 2014 This webcast presents an in depth research on miRNA biomarker development. It integrates PCR-based system that reduces the amount of sample required for full miRNome profiling and provides unparalleled reproducibility ...

NEW YORK CITY — March 11, 2014 — Exosome Diagnostics today announced the initial close of its Series B financing round with the raising of $27 million. Proceeds will be used to advance development of the Company’s proprietary platform technology ...